BRUSSELS, Belgium and CAMBRIDGE, Mass., June 19 /PRNewswire/ -- IDDI (International Drug Development Institute) and Cytel Inc. today reported entering into a strategic technology collaboration. The companies are cooperating to develop integrated systems and services for the randomization of treatment assignments for patients participating in clinical trials.
Flexible, centralized randomization techniques are increasingly used in sophisticated global biopharmaceutical clinical studies. IDDI and Cytel are combining innovations in centralized randomization methods with an advanced Web services-based software platform to provide integrated randomization and IVRS technology and services.
The CytelRAND(R) randomization engine is part of Cytel's FlexRandomizer(R), a suite of tools and services for randomization during clinical trial design, simulation, monitoring, and analysis. CytelRAND supports both fixed and dynamic randomization methods, implemented as a set of Web services, to ease integration and data exchange with third-party IVRS, EDC or drug supply systems. CytelRAND works with IDDI's Web-based patient registration and IVRS platform, ID-net(TM), to seamlessly access IDDI's secure, hosted trials infrastructure for centralized patient randomization in multi-center studies. ID-net manages patient registration and screening, prospective schedule of follow-up visits, entry of key clinical events, patient reported outcomes, unblinding of treatments, maintenance studies enrolment, and drug supply management.
The joint solution from IDDI and Cytel is being used in the design, simulation and operation of a major international oncology trial planning to recruit over 6,000 patients worldwide.
About IDDI
IDDI (International Drug Development Institute provides biostatistical expertise, data management services and innovative information systems to the pharmaceutical and biotechnology sector. ID-net(TM) uses web based and/or voice technologies to deploy applications anywhere in the world in accordance with the trial protocol specifications. IDDI is based in Brussels, Belgium, with offices in Cambridge, MA, and 24/7 support teams in both Europe and in North America.
About Cytel
Cytel Inc. is a leading provider of clinical trial consulting services and specialized statistical software for the bio-pharmaceutical, medical device, academic, and government research markets. Cytel's unique expertise in adaptive, flexible designs enables trial sponsors to improve drug development process efficiencies and trial success rates. Cytel's East(R) system is widely used by biostatisticians and clinicians in industry, academia, and the FDA to design, monitor and simulate group sequential, and adaptive clinical trials.
Cytel Inc.CONTACT: Catherine Indekeu of IDDI, +32 (0)2 646 89 18,catherine.indekeu@iddi.com; or Michael Weitz of Cytel Inc.,+1-617-528-7132, mike@cytel.com
